Sanofi's Rilzabrutinib Receives Breakthrough Therapy Designation in US, Orphan Drug Status in Japan for Warm Autoimmune Hemolytic Anemia
The US FDA has designated Sanofi's rilzabrutinib as a breakthrough therapy for warm autoimmune hemolytic anemia (wAIHA). Japan's Ministry of Health, Labour and Welfare has also granted the drug orphan drug status for the same condition.
Sanofi has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for rilzabrutinib (Wayrilz), an investigational oral Bruton's tyrosine kinase (BTK) inhibitor. The designation is for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disorder characterized by the premature destruction of red blood cells.
In parallel, Japan's Ministry of Health, Labour and Welfare has granted rilzabrutinib orphan drug designation for the same condition. These designations are based on clinical data from the ongoing LUMINA 2 Phase 2b study, which assessed the efficacy and safety of rilzabrutinib in patients with wAIHA. A Phase 3 study, LUMINA 3, is also underway comparing rilzabrutinib to a placebo.
Currently, no approved treatment specifically targets the underlying causes of wAIHA, a condition that can lead to anemia, fatigue, and severe organ damage. The FDA's breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening conditions where preliminary evidence suggests substantial improvement over available options. The orphan drug designation in Japan is for treatments intended for rare diseases with a significant unmet medical need.
Rilzabrutinib is already approved in the US and EU for the treatment of immune thrombocytopenia (ITP). These new designations reinforce Sanofi's commitment to advancing new therapies for rare diseases with limited or no existing treatment options.